Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683802 | 0.84 | ADORA2A (0.35) | CYP1A2 | |
| SCHEMBL120720 | 0.81 | ADORA2A (0.49) | — | |
| SCHEMBL6959953 | 0.81 | FDPS (0.38) | FDPSHDAC1HDAC6LTA4HMEN1 | |
| SCHEMBL28340215 | 0.80 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL6036330 | 0.71 | CDK1 (0.44) | FDPS | |
| SCHEMBL27734755 | 0.70 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL1748495 | 0.70 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL7797362 | 0.70 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL27558464 | 0.70 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL6055010 | 0.69 | FDPS (0.39) | FDPSHDAC1HDAC6LTA4HMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117441022-A | Sequential electroporation method | 美克斯细胞有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116916968-A | Oligonucleotide-based therapeutics and uses thereof | 托德·斯皮尔 | 2023-10-20 | — | — | CN | disclosed |
| US-20220211621-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | TLC BIOPHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| CN-107811971-B | Liposomes for drug delivery | 益普生生物制药公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2020220000-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | TLC BIOPHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10363031-B2 | Tissue thickness compensators for surgical staplers | ETHICON LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20160287249-A1 | TISSUE THICKNESS COMPENSATORS FOR CIRCULAR SURGICAL STAPLERS | CILAG GMBH INTERNATIONAL (CH) | 2016-10-06 | — | — | US | disclosed |
| US-9364233-B2 | Tissue thickness compensators for circular surgical staplers | ETHICON ENDO-SURGERY, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120241505-A1 | TISSUE THICKNESS COMPENSATORS FOR CIRCULAR SURGICAL STAPLERS | ETHICON ENDO-SURGERY, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2338525-A2 | Remote detection of substance delivery to cells | California Pacific Medical Center (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-1648299-A4 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | CALIFORNIA PACIFIC MED CENTER (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-1878594-A | Electrical devices and anti-scarring agents | ANGIOTECH INT AG (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1878514-A | Soft tissue implants and anti-scarring agents | ANGIOTECH INT AG (CH) | 2006-12-13 | — | — | CN | disclosed |
| EP-1648299-A1 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | California Pacific Medical Center (US) | 2006-04-26 | — | — | EP | disclosed |
| CN-1688349-A | Compositions and methods for coating medical implants | ANGIOTECH PHARM INC (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20050112065-A1 | Remote detection of substance delivery to cells | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-05-26 | — | — | US | disclosed |
| WO-2005016141-A1 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1299084-A2 | LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF | Inex Pharmaceuticals Corp. (CA) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002002077-A2 | LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF | INEX PHARMACEUTICALS CORPORATION (CA) | 2002-01-10 | — | — | WO | disclosed |
| US-4902717-A | TREATMENT OF ESTROGEN DEPENDENT NEOPLASTIC DISEASE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211621-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | LIPA, LPXN, SGMS2 | FDPS 1890/4885HDAC1 2878/4885HDAC6 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.